While MacMillan demonstrates strong business acumen with consistent 10% EPS growth and technological innovation in AI mammography, his blunt criticism of gender-biased medical practices reveals a leader willing to acknowledge uncomfortable truths in healthcare delivery, potentially risking industry relationships to advocate for change.